eXoZymes Reports $2.88 Million Net Loss in Q2 2026, Increases Cash Reserves

eXoZymes Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $2.88 million, or $0.33 per share, compared to a net loss of $2.36 million, or $0.28 per share, in the same period of 2025. For the six months ended June 30, 2026, the company incurred a net loss of $5.25 million, an increase of 24.5% from the $4.22 million loss reported in the prior year. The total operating costs for the first half of 2026 were $5.34 million, up 18.7% from $4.50 million in the same period of 2025, primarily driven by increased research and development expenses.

The company’s cash and cash equivalents increased significantly to $5.65 million as of June 30, 2026, from $3.04 million at the end of 2025, reflecting a net increase of $2.61 million, or 86%. This increase was largely attributed to the net proceeds of $5.86 million from equity offerings completed in June 2026. Total assets rose to $7.98 million, a 33.7% increase from $5.97 million at the end of the previous fiscal year. However, total liabilities also increased to $4.33 million, up 68.1% from $2.57 million, primarily due to the recognition of a warrant liability related to the recent equity offerings.

In terms of operational developments, eXoZymes has focused on expanding its research and development efforts, which saw costs rise by 85.7% year-over-year to $2.56 million for the first half of 2026. This increase was attributed to higher salary expenses, stock-based compensation, and laboratory costs, alongside a reduction in grant funding. The company continues to rely on government grants, with significant contributions from the National Science Foundation and the National Institutes of Health, which accounted for 85.8% of total grant reimbursements in the first half of 2026.

Strategically, eXoZymes has made significant moves to bolster its financial position, including the establishment of a wholly owned subsidiary, NCTx LLC, aimed at developing a rare plant-derived compound. The company also completed two equity offerings in June 2026, which provided essential funding to support its ongoing operations and research initiatives. Despite these efforts, management expressed concerns regarding the company's ability to continue as a going concern, citing anticipated funding shortfalls and the need for additional financial support to meet long-term obligations.

Looking ahead, eXoZymes plans to pursue further non-dilutive funding opportunities, including additional grants, and may seek further equity or debt financing. The company remains focused on advancing its synthetic biology platform, which aims to transform natural resources into valuable chemical products, although it acknowledges the inherent risks and uncertainties associated with technology development and market acceptance.